ERBB2 and breast carcinoma: In this study, we report that continued use of trastuzumab to induce resistance in PTEN deficient HER2+ breast cancer results in the epithelial to mesenchymal transition (EMT), as evident by reduced expression of epithelial markers and increased mesenchymal makers.